Wednesday, September 06, 2017 7:58:26 AM
VSTM - 3.84 Pre-market now at 5.31/5.34
Verastem's Phase 3 DUO Study Showed Statistically Significant Improvement
BZ: Verastem's Duvelisib Receives Fast Track Designation from the FDA
Verastem's Phase 3 DUO Study Showed Statistically Significant Improvement
BZ: Verastem's Duvelisib Receives Fast Track Designation from the FDA
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
